Tricyclic Antidepressants (TCAs) Are the Antidepressants of Choice for IBS-D
For IBS-D, use tricyclic antidepressants (TCAs), not SSRIs. The 2022 AGA guidelines specifically recommend TCAs for IBS patients, while explicitly recommending against SSRIs 1.
Why TCAs Work for IBS-D
TCAs provide multiple beneficial mechanisms for IBS-D:
- Reduce diarrhea through anticholinergic effects that slow gut motility
- Decrease abdominal pain through central and peripheral neuromodulation
- Improve global IBS symptoms independent of any antidepressant effects
- Work through inhibition of serotonin/norepinephrine reuptake plus blockade of muscarinic, α1-adrenergic, and histamine receptors 1
The evidence shows TCAs achieve global symptom relief (RR 0.67) and abdominal pain relief (RR 0.76-0.94) compared to placebo 1.
Specific TCA Options for IBS-D
Start with low-dose amitriptyline 10 mg at bedtime - this has proven efficacy specifically in IBS-D patients 1. Other effective TCAs studied include:
- Amitriptyline (most studied, 3 trials)
- Desipramine (2 trials)
- Imipramine (particularly effective for pain per recent meta-analysis 2)
- Trimipramine, doxepin (less data)
Clinical dosing: While most studies used 50+ mg daily, clinical practice typically uses lower doses (10-25 mg) to minimize side effects while maintaining benefit 1.
Why NOT SSRIs for IBS-D
The AGA explicitly recommends against SSRIs for IBS (conditional recommendation, low certainty evidence) 1, 3. Key problems:
- SSRIs increase gastric and intestinal motility, which worsens diarrhea
- Failed to show significant improvement in global symptoms (RR 0.74, CI 0.52-1.06) or abdominal pain
- The confidence interval upper boundary suggests possible worsening of symptoms 1
- May be useful only when anxiety/hypervigilance dominates, but not for pain or diarrhea 4
Critical Practical Points
Anticholinergic side effects of TCAs are actually therapeutic in IBS-D - they cause constipation and reduce diarrhea, which is beneficial. However, these same effects make TCAs problematic for IBS-C patients 3.
Time to effect: Benefits may take several weeks to manifest and are independent of mood effects 1. Plan for 6-12 months of treatment after initial response to prevent relapse 4.
Common pitfall: Don't use SSRIs thinking all antidepressants work the same - their prokinetic effects can worsen IBS-D symptoms.
Alternative Consideration
SNRIs (serotonin-norepinephrine reuptake inhibitors) like venlafaxine may be effective for pain based on their dual mechanism, and recent meta-analysis shows benefit for depression and quality of life 2, but clinical trial data in IBS remains limited 1, 3.